Publications by authors named "Graham Wetherill"

Claim this Profile
R
Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I-III Resected NSCLC Without Known EGFR Mutations: The RESECT Study.
Jhanelle E Gray, Rachel J Salomonsen, Ignacio Diaz Perez, Alice Wang, Ling Cai, Graham Wetherill

Drugs Real World Outcomes· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS).
Vallerie V McLaughlin, Richard Channick, Nick H Kim, Robert P Frantz, John W McConnell, Graham Wetherill

Pulm Circ· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases.
Patricia Biedermann, Rose Ong, Alexander Davydov, Alexandra Orlova, Philip Solovyev, Graham Wetherill

BMC Med Res Methodol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
Maria J G T Vehreschild, Surabhi Taori, Simon D Goldenberg, Florian Thalhammer, Emilio Bouza, Graham Wetherill

Eur J Clin Microbiol Infect Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
Maria J G T Vehreschild, Surabhi Taori, Simon D Goldenberg, Florian Thalhammer, Emilio Bouza, Graham Wetherill

Eur J Clin Microbiol Infect Dis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasonographic evaluation of vitreous degeneration in normal dogs.
Julien J Labruyère, Claudia Hartley, Katherine Rogers, Graham Wetherill, J Fraser McConnell

Vet Radiol Ultrasound· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Alan Menter, Tiffani K Hamilton, Darryl P Toth, Hoi M Leung, Graham Wetherill

Int J Dermatol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Craig L Leonardi, Darryl Toth, Jennifer C Cather, Richard G B Langley, Winifred Werther, Graham Wetherill

Dermatology· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
Richard G B Langley, Wayne P Carey, Elyse S Rafal, Stephen K Tyring, Ivor Caro, Graham Wetherill

Clin Ther· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
Peter Rieckmann, Paul O'Connor, Gordon S Francis, Graham Wetherill, Enrica Alteri

Drug Saf· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis